Cytometry News and Research

RSS

Three doses of inactivated BBIBP-CorV SARS-CoV-2 vaccine induce robust B and T cell responses

To investigate the immune memory sustainability of SARS-CoV-2-specific B cells and T cells, stimulated by the inactivated vaccine, and the potential need for a third booster dose in healthcare workers (HCWs), a non-randomized trial was undertaken by researchers at Sun Yat-sen University in Guangzhou, China. the research is posted online on the medRxiv* preprint server.

17 Sep 2021

Unique imaging technique sheds light on how cells related to IBD affect intestinal tissues

New "maps" of hundreds of thousands of cells related to inflammatory bowel disease shed greater light on their effects on intestinal tissues through a newly utilized imaging technique called "imaging mass cytometry."

16 Sep 2021

Antiviral compound RG10 acts via intracellular SARS-CoV-2-ER dynamics

A new study describes a small molecule referred to as RG10 that may have potent antiviral activity against SARS-CoV-2 in human cells.

16 Sep 2021

Analysis of the immune landscape in mild-to-moderate COVID-19

A new study includes an analysis of plasma cytokine levels, peripheral blood immune cell composition, and SARS-CoV-2 specific Igs in COVID-19.

15 Sep 2021

Deep profiling of SARS-CoV-2 immune response amongst the mildly symptomatic

In a research paper recently uploaded to the medRxiv* preprint server by Capelle et al. (September 2nd, 2021), the immune response of mild and hospitalized COVID-19 patients is compared, finding that early T-cell response is a vital indicator of SARS-CoV-2 disease severity.

15 Sep 2021

Metabolic and immune markers as tools for risk stratification and monitoring in COVID-19

In a new study posted to the medRxiv* server scientists from Weil Cornell University and Stony Brook University in New York attempted to identify the metabolic and immune markers associated with severe COVID-19 disease using high-throughput targeted nuclear magnetic resonance (NMR) spectroscopy and high-dimensional flow cytometry. This will facilitate risk stratification, monitoring, and therapeutic interventions in COVID-19 patients.

14 Sep 2021

No evidence of pre-existing antibody and B cell immunity against SARS-CoV-2 in unexposed adults

A group of researchers analyzed the B cell response to SARS-CoV-2 in unexposed individuals.

10 Sep 2021

Allergic reactions provide protection against yeast-triggered asthma, research shows

We think of asthma and other allergic diseases as unnecessary aberrant immune responses that do more harm than good. However, new evidence by an international team led by researchers at Baylor College of Medicine shows that some allergic reactions provide necessary protection against highly invasive and potentially lethal infectious agents, such as yeast.

9 Sep 2021

New vaccinia-based COVID-19 vaccine candidate induces robust, durable immune responses

Researchers in Australia have developed a coronavirus disease 2019 (COVID-9) vaccine that induced robust and long-lived humoral and cellular immune responses against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in both young and aging mice.

8 Sep 2021

Researchers study the role of low-density granulocytes in COVID-19

Information on granulocytes helps to understand mechanisms associated with covid-19 and other infectious diseases. Such information also promotes the development of better diagnostic methods and therapies.

30 Aug 2021

Could soluble CD24 offer some hope against severe COVID-19?

A recent randomized phase III trial conducted by researchers at the Ohio State University, Columbus, OH, US, evaluated the impact of CD24Fc in severe COVID-19 patients and showed promising clinical efficacy. This study is available as a preprint on the medRxiv* server.

26 Aug 2021

MSK researchers identify potential biomarker of response to checkpoint immunotherapy

In recent years, immune-based treatments for cancer have buoyed the hopes of doctors and patients alike. Drugs called immune checkpoint inhibitors have provided lifesaving benefits to a growing list of people with several types of cancer, including melanoma, lung cancer, bladder cancer, and many more.

25 Aug 2021

Persistence of Anti-PF4 levels in VITT patients four months after AstraZeneca COVID-19 vaccine

A study published on medRxiv* preprint server reported the over-time changes in the ability of the serum to activate platelets in vitro.

25 Aug 2021

Scientists identify a potent neutralizing nanobody against SARS-CoV-1

In a recently published article in the journal Virologica Sinica, scientists have described the development and validation of a potent nanobody that targets the receptor-binding domain (RBD) of severe acute respiratory syndrome coronavirus (SARS-CoV). The nanobody efficiently and specifically blocks the interaction between RBD and angiotensin-converting enzyme 2 (ACE2) and neutralizes the virus.

19 Aug 2021

COVIDome Explorer online portal launched to accelerate COVID-19 research on a global scale

To further accelerate COVID-19 research on a global scale, investigators from the University of Colorado Anschutz Medical Campus have created a multidimensional dataset, known as the COVIDome dataset, derived from hospitalized COVID-19 patients versus negative controls.

17 Aug 2021

Biotium releases new ExoBrite EV Membrane Staining Kits

Biotium, a leading supplier and inventor of fluorescent cellular probes for life science research, announces the release of new ExoBrite™ EV Membrane Staining Kits.

17 Aug 2021

Discovery of highly potent neutralizing monoclonal antibodies against SARS-CoV-2

A new study published in the journal Nature Communications has reported two neutralizing antibodies, namely, nCoVmab1 and nCoVmab2, which are potent against SARS-CoV-2.

13 Aug 2021

New insight into impact of SARS-CoV-2 mutations on receptor binding

A recent study by Canadian researchers, currently available on the bioRxiv* preprint server, contributes to the growing body of literature on emerging variants of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by appraising the impact of single mutations on their overall antigenicity and binding affinity for the angiotensin-converting enzyme 2 (ACE2) receptor.

9 Aug 2021

Long COVID may be due to persistent immune disturbances

A new study discusses abnormalities in the immune response following COVID-19 in samples collected from patients who have recovered from COVID-19.

8 Aug 2021

University of Pittsburgh invests in Canopy Biosciences’ ChipCytometry instrument for spatial biology

Canopy Biosciences, a Bruker Company, today announced that the University of Pittsburgh will add ChipCytometry for high-plex single-cell spatial biology to its capabilities at the Unified Flow Core in the Department of Immunology

From Bruker Nano Surfaces and Metrology 6 Aug 2021